Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer

Recently, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated the guidelines on HER2 testing for invasive breast cancer. Little is known about the impact of the guidelines update. We aimed to study the impact of the 2018 ASCO/CAP HER2 testing guidelines upda...

Full description

Saved in:
Bibliographic Details
Published in:Pathology, research and practice research and practice, 2019-02, Vol.215 (2), p.251-255
Main Authors: Xu, Bin, Shen, Jianguo, Guo, Wenhao, Zhao, Wenhe, Zhuang, Yiyu, Wang, Linbo
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - analysis
Breast cancer
Breast Neoplasms - classification
Breast Neoplasms - mortality
Female
Fluorescence in situ hybridization (FISH)
Guidelines as Topic
HER2
Humans
In Situ Hybridization, Fluorescence - methods
Kaplan-Meier Estimate
Receptor, ErbB-2 - analysis
The 2018 ASCO/CAP guidelines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c353t-73e279fcb1432f19a691ab2f5778bb41f9409cefefb116a072740268295e6ece3
cites cdi_FETCH-LOGICAL-c353t-73e279fcb1432f19a691ab2f5778bb41f9409cefefb116a072740268295e6ece3
container_end_page 255
container_issue 2
container_start_page 251
container_title Pathology, research and practice
container_volume 215
creator Xu, Bin
Shen, Jianguo
Guo, Wenhao
Zhao, Wenhe
Zhuang, Yiyu
Wang, Linbo
description Recently, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated the guidelines on HER2 testing for invasive breast cancer. Little is known about the impact of the guidelines update. We aimed to study the impact of the 2018 ASCO/CAP HER2 testing guidelines update. We compared the HER2 FISH results interpreted by 2013 and 2018 ASCO/CAP guidelines in 331 cases of invasive breast cancers. We also analyzed the pathological features and clinical outcomes of these cases. In comparing to the 2013 ASCO/CAP guidelines, the HER2 negative rate was increased significantly from 62.5% to 75.8%(P 
doi_str_mv 10.1016/j.prp.2018.10.035
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2132727716</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0344033818311993</els_id><sourcerecordid>2132727716</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-73e279fcb1432f19a691ab2f5778bb41f9409cefefb116a072740268295e6ece3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoWj9-gBfJ0cvWmWS7H3gqpdqCoPhxE0I2O9GUdndNdgX_vSlVj56GmXnfl5mHsXOEMQJmV6tx57uxACxiPwY52WMjzLBIIJO4z0Yg0zQBKYsjdhzCCgBySPGQHUlIowvEiL0uN502PW8t79-Jb7P49Gl2fzWbPvDF_FHwt8HVtHYNBT50te6J29bvVj2F3jVvvPriN8unBXcNrzzp0HOjG0P-lB1YvQ509lNP2MvN_Hm2SO7ub5ez6V1i5ET2SS5J5KU1FaZSWCx1VqKuhJ3keVFVKdoyhdKQJVshZhpykacgskKUE8rIkDxhl7vczrcfQzxKbVwwtF7rhtohKIFSRFOOWZTiTmp8G4InqzrvNtp_KQS1hapWcdKpLYjtKEKNnouf-KHaUP3n-KUYBdc7AcUnPx15FYyjSKB2nkyv6tb9E_8N79GDcw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2132727716</pqid></control><display><type>article</type><title>Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer</title><source>Elsevier</source><creator>Xu, Bin ; Shen, Jianguo ; Guo, Wenhao ; Zhao, Wenhe ; Zhuang, Yiyu ; Wang, Linbo</creator><creatorcontrib>Xu, Bin ; Shen, Jianguo ; Guo, Wenhao ; Zhao, Wenhe ; Zhuang, Yiyu ; Wang, Linbo</creatorcontrib><description>Recently, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated the guidelines on HER2 testing for invasive breast cancer. Little is known about the impact of the guidelines update. We aimed to study the impact of the 2018 ASCO/CAP HER2 testing guidelines update. We compared the HER2 FISH results interpreted by 2013 and 2018 ASCO/CAP guidelines in 331 cases of invasive breast cancers. We also analyzed the pathological features and clinical outcomes of these cases. In comparing to the 2013 ASCO/CAP guidelines, the HER2 negative rate was increased significantly from 62.5% to 75.8%(P &lt; 0.05), and 13.3% changed from equivocal to negative by the 2018 guidelines. Our findings indicate that the guidelines update significantly increased the rate of negative results. The reclassification of the equivocal results by the 2018 guidelines is the main reason for this change. Patients with HER2 equivocal results were associated with larger tumor size and higher Ki67 index than those with negative results, while clinical outcomes were similar between them.</description><identifier>ISSN: 0344-0338</identifier><identifier>EISSN: 1618-0631</identifier><identifier>DOI: 10.1016/j.prp.2018.10.035</identifier><identifier>PMID: 30420102</identifier><language>eng</language><publisher>Germany: Elsevier GmbH</publisher><subject>Biomarkers, Tumor - analysis ; Breast cancer ; Breast Neoplasms - classification ; Breast Neoplasms - mortality ; Female ; Fluorescence in situ hybridization (FISH) ; Guidelines as Topic ; HER2 ; Humans ; In Situ Hybridization, Fluorescence - methods ; Kaplan-Meier Estimate ; Receptor, ErbB-2 - analysis ; The 2018 ASCO/CAP guidelines</subject><ispartof>Pathology, research and practice, 2019-02, Vol.215 (2), p.251-255</ispartof><rights>2018</rights><rights>Copyright © 2018. Published by Elsevier GmbH.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-73e279fcb1432f19a691ab2f5778bb41f9409cefefb116a072740268295e6ece3</citedby><cites>FETCH-LOGICAL-c353t-73e279fcb1432f19a691ab2f5778bb41f9409cefefb116a072740268295e6ece3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30420102$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Bin</creatorcontrib><creatorcontrib>Shen, Jianguo</creatorcontrib><creatorcontrib>Guo, Wenhao</creatorcontrib><creatorcontrib>Zhao, Wenhe</creatorcontrib><creatorcontrib>Zhuang, Yiyu</creatorcontrib><creatorcontrib>Wang, Linbo</creatorcontrib><title>Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer</title><title>Pathology, research and practice</title><addtitle>Pathol Res Pract</addtitle><description>Recently, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated the guidelines on HER2 testing for invasive breast cancer. Little is known about the impact of the guidelines update. We aimed to study the impact of the 2018 ASCO/CAP HER2 testing guidelines update. We compared the HER2 FISH results interpreted by 2013 and 2018 ASCO/CAP guidelines in 331 cases of invasive breast cancers. We also analyzed the pathological features and clinical outcomes of these cases. In comparing to the 2013 ASCO/CAP guidelines, the HER2 negative rate was increased significantly from 62.5% to 75.8%(P &lt; 0.05), and 13.3% changed from equivocal to negative by the 2018 guidelines. Our findings indicate that the guidelines update significantly increased the rate of negative results. The reclassification of the equivocal results by the 2018 guidelines is the main reason for this change. Patients with HER2 equivocal results were associated with larger tumor size and higher Ki67 index than those with negative results, while clinical outcomes were similar between them.</description><subject>Biomarkers, Tumor - analysis</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - classification</subject><subject>Breast Neoplasms - mortality</subject><subject>Female</subject><subject>Fluorescence in situ hybridization (FISH)</subject><subject>Guidelines as Topic</subject><subject>HER2</subject><subject>Humans</subject><subject>In Situ Hybridization, Fluorescence - methods</subject><subject>Kaplan-Meier Estimate</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>The 2018 ASCO/CAP guidelines</subject><issn>0344-0338</issn><issn>1618-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMoWj9-gBfJ0cvWmWS7H3gqpdqCoPhxE0I2O9GUdndNdgX_vSlVj56GmXnfl5mHsXOEMQJmV6tx57uxACxiPwY52WMjzLBIIJO4z0Yg0zQBKYsjdhzCCgBySPGQHUlIowvEiL0uN502PW8t79-Jb7P49Gl2fzWbPvDF_FHwt8HVtHYNBT50te6J29bvVj2F3jVvvPriN8unBXcNrzzp0HOjG0P-lB1YvQ509lNP2MvN_Hm2SO7ub5ez6V1i5ET2SS5J5KU1FaZSWCx1VqKuhJ3keVFVKdoyhdKQJVshZhpykacgskKUE8rIkDxhl7vczrcfQzxKbVwwtF7rhtohKIFSRFOOWZTiTmp8G4InqzrvNtp_KQS1hapWcdKpLYjtKEKNnouf-KHaUP3n-KUYBdc7AcUnPx15FYyjSKB2nkyv6tb9E_8N79GDcw</recordid><startdate>201902</startdate><enddate>201902</enddate><creator>Xu, Bin</creator><creator>Shen, Jianguo</creator><creator>Guo, Wenhao</creator><creator>Zhao, Wenhe</creator><creator>Zhuang, Yiyu</creator><creator>Wang, Linbo</creator><general>Elsevier GmbH</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201902</creationdate><title>Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer</title><author>Xu, Bin ; Shen, Jianguo ; Guo, Wenhao ; Zhao, Wenhe ; Zhuang, Yiyu ; Wang, Linbo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-73e279fcb1432f19a691ab2f5778bb41f9409cefefb116a072740268295e6ece3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biomarkers, Tumor - analysis</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - classification</topic><topic>Breast Neoplasms - mortality</topic><topic>Female</topic><topic>Fluorescence in situ hybridization (FISH)</topic><topic>Guidelines as Topic</topic><topic>HER2</topic><topic>Humans</topic><topic>In Situ Hybridization, Fluorescence - methods</topic><topic>Kaplan-Meier Estimate</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>The 2018 ASCO/CAP guidelines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Bin</creatorcontrib><creatorcontrib>Shen, Jianguo</creatorcontrib><creatorcontrib>Guo, Wenhao</creatorcontrib><creatorcontrib>Zhao, Wenhe</creatorcontrib><creatorcontrib>Zhuang, Yiyu</creatorcontrib><creatorcontrib>Wang, Linbo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology, research and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Bin</au><au>Shen, Jianguo</au><au>Guo, Wenhao</au><au>Zhao, Wenhe</au><au>Zhuang, Yiyu</au><au>Wang, Linbo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer</atitle><jtitle>Pathology, research and practice</jtitle><addtitle>Pathol Res Pract</addtitle><date>2019-02</date><risdate>2019</risdate><volume>215</volume><issue>2</issue><spage>251</spage><epage>255</epage><pages>251-255</pages><issn>0344-0338</issn><eissn>1618-0631</eissn><abstract>Recently, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated the guidelines on HER2 testing for invasive breast cancer. Little is known about the impact of the guidelines update. We aimed to study the impact of the 2018 ASCO/CAP HER2 testing guidelines update. We compared the HER2 FISH results interpreted by 2013 and 2018 ASCO/CAP guidelines in 331 cases of invasive breast cancers. We also analyzed the pathological features and clinical outcomes of these cases. In comparing to the 2013 ASCO/CAP guidelines, the HER2 negative rate was increased significantly from 62.5% to 75.8%(P &lt; 0.05), and 13.3% changed from equivocal to negative by the 2018 guidelines. Our findings indicate that the guidelines update significantly increased the rate of negative results. The reclassification of the equivocal results by the 2018 guidelines is the main reason for this change. Patients with HER2 equivocal results were associated with larger tumor size and higher Ki67 index than those with negative results, while clinical outcomes were similar between them.</abstract><cop>Germany</cop><pub>Elsevier GmbH</pub><pmid>30420102</pmid><doi>10.1016/j.prp.2018.10.035</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0344-0338
ispartof Pathology, research and practice, 2019-02, Vol.215 (2), p.251-255
issn 0344-0338
1618-0631
language eng
recordid cdi_proquest_miscellaneous_2132727716
source Elsevier
subjects Biomarkers, Tumor - analysis
Breast cancer
Breast Neoplasms - classification
Breast Neoplasms - mortality
Female
Fluorescence in situ hybridization (FISH)
Guidelines as Topic
HER2
Humans
In Situ Hybridization, Fluorescence - methods
Kaplan-Meier Estimate
Receptor, ErbB-2 - analysis
The 2018 ASCO/CAP guidelines
title Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T18%3A39%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20the%202018%20ASCO/CAP%20HER2%20guidelines%20update%20for%20HER2%20testing%20by%20FISH%20in%20breast%20cancer&rft.jtitle=Pathology,%20research%20and%20practice&rft.au=Xu,%20Bin&rft.date=2019-02&rft.volume=215&rft.issue=2&rft.spage=251&rft.epage=255&rft.pages=251-255&rft.issn=0344-0338&rft.eissn=1618-0631&rft_id=info:doi/10.1016/j.prp.2018.10.035&rft_dat=%3Cproquest_cross%3E2132727716%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c353t-73e279fcb1432f19a691ab2f5778bb41f9409cefefb116a072740268295e6ece3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2132727716&rft_id=info:pmid/30420102&rfr_iscdi=true